ANDA 71717, held by Rising Pharmaceuticals. Flurazepam Hydrochloride.
As of Nov 19, 2026, ANDA 71717 (Flurazepam Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Jul 31, 1991, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 31, 1991 | Original application | Approved | None posted |
| Flurazepam Hydrochloride30MG · capsule;oral | Flurazepam Hydrochloride | Discontinued |
| Flurazepam Hydrochloride15MG · capsule;oral | Flurazepam Hydrochloride | Discontinued |
| Dec 16, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 24, 1994 | Supplement 2Manufacturing | Approved | None posted |
| Aug 25, 1993 | Supplement 1Labeling | Approved | None posted |
| Jul 31, 1991 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters